[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:chronic-myeloid-leukemia-bcr-abl1-positive":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":331},"Chronic Myeloid Leukemia, BCR-ABL1 Positive",91,77,[8,16,23,29,36,42,48,54,60,66,72,78,85,91,98,104,110,116,122,128,134,140,146,152,158,164,170,175,181,186,192,198,204,210,216,222,227,233,239,245,251,257,264,270,275,281,287,293,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04925479","Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:57.705506Z","2026-07-05T05:32:16.796686Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05007873","ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase",[20],"Phase 2","2026-08-03T02:39:51.946262Z","2026-05-05T02:43:29.710118Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06308588","Phase I\u002FII Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:16:17.877565Z","2026-05-05T02:43:29.682278Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06401603","A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia",[33],"Phase 1","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.388278Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06817720","Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[20],"2026-08-26T02:17:16.126291Z","2026-05-05T02:43:29.285437Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06236724","Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.",[20],"2026-08-26T02:19:05.360997Z","2026-05-05T02:43:29.199644Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06163430","A Phase 1\u002F2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)",[12],"2026-08-26T02:17:23.750999Z","2026-05-05T02:43:28.654539Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06629584","Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia",[20],"2026-08-26T02:17:22.153941Z","2026-05-05T02:43:28.480225Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT07269470","Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase",[20],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:28.219978Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT04838041","Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation",[20],"2026-08-26T02:16:00.194860Z","2026-05-05T02:43:27.920762Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT06423911","Study of Olverembatinib (HQP1351) in Patients With CP-CML",[82],"Phase 3","2026-08-26T02:16:38.053590Z","2026-05-05T02:43:27.755425Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT06088888","TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia",[33],"2026-08-26T02:16:01.910993Z","2026-05-05T02:43:27.612066Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":96,"content_modified":97},"NCT04877522","Asciminib Roll-over Study",[95],"Phase 4","2026-08-26T02:19:28.327680Z","2026-05-05T02:43:27.182842Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT05304377","A Phase 1a\u002F1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia",[33],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:26.926295Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT04260022","Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",[33],"2026-08-26T02:19:10.436356Z","2026-05-05T02:35:31.763995Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT01746836","Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",[20],"2026-08-26T02:19:12.219640Z","2026-04-29T02:57:57.143397Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06802315","Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)",[20],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:29.503051Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT03595917","ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML",[33],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:29.224482Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT03533816","Expanded\u002FActivated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide",[33],"2026-08-26T02:16:47.762107Z","2026-05-05T02:43:28.956477Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":138,"content_modified":139},"NCT06994676","A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias",[33],"2026-08-26T02:18:41.390601Z","2026-05-05T02:43:27.517921Z",{"nct_id":141,"title":142,"phases":143,"status":13,"updated_at":144,"content_modified":145},"NCT02115295","Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",[20],"2026-08-26T02:19:11.399072Z","2026-05-05T02:35:31.645116Z",{"nct_id":147,"title":148,"phases":149,"status":13,"updated_at":150,"content_modified":151},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[12],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":153,"title":154,"phases":155,"status":13,"updated_at":156,"content_modified":157},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[82],"2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.764159Z",{"nct_id":159,"title":160,"phases":161,"status":13,"updated_at":162,"content_modified":163},"NCT07566377","Cord Blood Transplantation in Children and Young Adults With Blood Cancer",[20],"2026-08-26T02:15:09.079045Z","2026-05-13T02:55:06.730274Z",{"nct_id":165,"title":166,"phases":167,"status":13,"updated_at":168,"content_modified":169},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":171,"title":172,"phases":173,"status":13,"updated_at":34,"content_modified":174},"NCT05794880","MCW Alpha\u002FBeta T-Cell and B-Cell Depletion With Targeted ATG Dosing",[],"2026-05-05T02:43:29.363482Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT07052370","TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies",[33],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.201965Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":126,"content_modified":185},"NCT05031897","Two Step Haplo With Radiation Conditioning",[20],"2026-05-05T02:43:29.158573Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT06047886","UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy",[33],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:29.130088Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT02727803","Personalized NK Cell Therapy in CBT",[20],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:29.030294Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients",[20],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.020712Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":208,"content_modified":209},"NCT06680661","ABBA CORD: dCBT w\u002F Abatacept for aGVHD Prophylaxis",[20],"2026-08-26T02:17:14.343713Z","2026-05-05T02:43:28.824003Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT06859424","A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation",[20],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:28.740200Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT04959175","Phase I\u002FII Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies",[12],"2026-08-26T02:15:23.202838Z","2026-05-05T02:43:28.644953Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":168,"content_modified":226},"NCT05800210","Alpha\u002FBeta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases",[20],"2026-05-05T02:43:28.348250Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT06028828","Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation",[20],"2026-08-26T02:16:09.452956Z","2026-05-05T02:43:28.300701Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT05857969","Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling",[33],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.220097Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[20],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[20],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":255,"content_modified":256},"NCT05092451","Phase I\u002FII Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:27.847376Z",{"nct_id":258,"title":259,"phases":260,"status":13,"updated_at":262,"content_modified":263},"NCT06398457","Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies",[261],"Early Phase 1","2026-08-26T02:15:53.461103Z","2026-05-05T02:43:27.839395Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT03326921","HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant",[33],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:27.769481Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":138,"content_modified":274},"NCT03630991","Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",[33],"2026-05-05T02:43:27.485890Z",{"nct_id":276,"title":277,"phases":278,"status":13,"updated_at":279,"content_modified":280},"NCT03964506","Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant",[261],"2026-08-26T02:18:44.395098Z","2026-05-05T02:43:27.480390Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":285,"content_modified":286},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[20],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":288,"title":289,"phases":290,"status":13,"updated_at":291,"content_modified":292},"NCT07214688","Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies",[20],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:27.479044Z",{"nct_id":294,"title":295,"phases":296,"status":13,"updated_at":297,"content_modified":298},"NCT06904066","Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",[33],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:27.428326Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT03970096","Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)",[20],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:26.980874Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT06013423","Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases",[20],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:26.947230Z",[312,316,320,324,328],{"biomarker":313,"count":314,"slug":315},"BCR\u002FABL1 Fusion Gene",27,"bcr-abl1-fusion-gene",{"biomarker":317,"count":318,"slug":319},"t(9;22)(q34.1;q11.2)",10,"t-9-22-q34-1-q11-2",{"biomarker":321,"count":322,"slug":323},"HLA Complex",8,"hla-complex",{"biomarker":325,"count":326,"slug":327},"CD19 Gene",3,"cd19-gene",{"biomarker":329,"count":326,"slug":330},"T315I","t315i",[332,336,340,344,348,351,354,358,362,365,368,371,374,377,381,384,387,391,395,398,402,405,409,412],{"state":333,"count":334,"slug":335},"Texas",37,"texas",{"state":337,"count":338,"slug":339},"New York",22,"new-york",{"state":341,"count":342,"slug":343},"California",16,"california",{"state":345,"count":346,"slug":347},"Maryland",13,"maryland",{"state":349,"count":346,"slug":350},"Pennsylvania","pennsylvania",{"state":352,"count":346,"slug":353},"Washington","washington",{"state":355,"count":356,"slug":357},"Florida",12,"florida",{"state":359,"count":360,"slug":361},"Georgia",11,"georgia",{"state":363,"count":360,"slug":364},"Massachusetts","massachusetts",{"state":366,"count":360,"slug":367},"Ohio","ohio",{"state":369,"count":318,"slug":370},"Alabama","alabama",{"state":372,"count":318,"slug":373},"Michigan","michigan",{"state":375,"count":318,"slug":376},"Wisconsin","wisconsin",{"state":378,"count":379,"slug":380},"Oregon",9,"oregon",{"state":382,"count":322,"slug":383},"North Carolina","north-carolina",{"state":385,"count":322,"slug":386},"Tennessee","tennessee",{"state":388,"count":389,"slug":390},"Illinois",7,"illinois",{"state":392,"count":393,"slug":394},"Missouri",6,"missouri",{"state":396,"count":393,"slug":397},"Utah","utah",{"state":399,"count":400,"slug":401},"Colorado",5,"colorado",{"state":403,"count":400,"slug":404},"Kansas","kansas",{"state":406,"count":407,"slug":408},"Arizona",4,"arizona",{"state":410,"count":407,"slug":411},"District of Columbia","district-of-columbia",{"state":413,"count":407,"slug":414},"Indiana","indiana"]